Search

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

EHA-PTHiT Mini Hematology Tutorial

EHA and the Polish Society of Hematology and Transfusion (PTHiT) are happy to present the second virtual 'mini Tutorial'. This two-day meeting aims to assess and increase your knowledge of the treatment of myeloid and lymphoid diseases.

Read more

Registration

Register here

The registration fee for the ESH-EBMT-EHA 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Read more

The EHA Guidelines Workshop, a meaningful and successful first Series!

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Bleeding and thrombosis
EHA Guidelines on management of antithrombotic treatments…

Read more